GlassScriptPhysician profile
Nancy Jane Newman
NPI 1568460871
$2,500.34
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $487 · 2020: $211 · 2021: $600 · 2022: $630 · 2023: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $572.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $589.66 | 2021-2023 | Ova1 |
| Abbvie INC. | $473.00 | 2019-2023 | |
| Amgen INC. | $323.13 | 2019-2022 | |
| Hologic Sales and Service, LLC | $144.29 | 2019-2023 | Aptima, Affirm Prone Biopsy System |
| Allergan, INC. | $143.29 | 2019-2020 | |
| Therapeuticsmd, INC. | $135.56 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $135.00 | 2023 | Fasenra |
| Pfizer INC. | $124.99 | 2019-2023 | |
| Novo Nordisk INC | $106.41 | 2023 | Wegovy |
| Exact Sciences Corporation | $50.84 | 2023 | Cologuard Collection Kit |
| Agile Therapeutics, INC. | $46.90 | 2021-2023 | Twirla |
| Astellas Pharma US INC | $44.56 | 2023 | Myrbetriq |
| Avion Pharmaceuticals | $25.37 | 2022-2023 | Balcoltra |
| Urovant Sciences INC | $21.70 | 2021 | |
| Exeltis, USA INC. | $15.81 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $15.15 | 2019 | |
| Daiichi Sankyo INC. | $14.57 | 2020 | |
| Mayne Pharma Commercial LLC | $14.27 | 2022 | |
| Merck Sharp & Dohme LLC | $13.75 | 2019 | |
| Lupin INC. | $13.62 | 2019 | |
| Alfasigma USA, INC. | $12.89 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.85 | 2020 | |
| Zyla Life Sciences, INC. | $11.67 | 2020 | |
| Vertical Pharmaceuticals, LLC | $11.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Newman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.